Journal of Neuro-Oncology

, Volume 118, Issue 1, pp 155–162 | Cite as

Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series

Clinical Study


There is comparatively limited therapy for recurrent primary central nervous system lymphoma (PCNSL). Salvage therapies include re-challenge with high-dose methotrexate (HD-MTX), whole brain radiotherapy, temozolomide, topotecan and premetrexed. Bendamustine is a novel bifunctional alkylator with established activity in B cell systemic lymphomas but never previously evaluated in PCNSL. The objective of the current study was to assess response and toxicity of bendamustine in recurrent PCNSL following prior salvage therapy in a retrospective case series. Twelve adults [six males; six females: median age 59 years (range 43–74)] with HD-MTX refractory recurrent PCNSL were treated with bendamustine. All patients were treated at second recurrence following failure of prior salvage therapy. A cycle of bendamustine was defined as two consecutive days of treatment (100 mg/m2/day) administered once every 4 weeks (maximum number of cycles 6). Toxicities seen were Grade 2 (24 episodes in 10 patients) and 3 (10 episodes in 5 patients) only and included lymphopenia (8 patients), hyperglycemia (7 patients), fatigue (7 patients) and nausea (4 patients). The median number of cycles of therapy was 3.5 (range 1–6). Radiographic response was progressive disease in 5 (42 %), stable disease in 1 (8 %), partial response in 3 (25 %) and complete response in 3 (25 %). Median progression free survival (PFS) was 3.5 months (range 1–14 months) and 6-month PFS was 33 %. In this small retrospective series of select patients with recurrent PCNSL refractory to HD-MTX, bendamustine appears to have modest single agent activity with manageable toxicity. Confirmation in a larger series of similar patients is required.


Bendamustine Primary CNS lymphoma (PCNSL) High-dose methotrexate (HD-MTX) refractory 



Marc C. Chamberlain collected and analyzed data. No personal communications cited in the manuscript.

Conflict of interest

The author reports no conflict of interest.


  1. 1.
    Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281–1288. doi: 10.1200/JCO.2005.04.8819 PubMedCrossRefGoogle Scholar
  2. 2.
    Thiel E, Korfel A, Martus P et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomized, non-inferiority trial. Lancet Oncol 11:1036–1047. doi: 10.1016/S1470-2045(10)70229-1 PubMedCrossRefGoogle Scholar
  3. 3.
    lllerhaus G, Marks R, Ihorst G et al (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24:3865–3870. doi: 10.1200/JCO.2006.06.2117 CrossRefGoogle Scholar
  4. 4.
    Colombat P, Lemevel A, Bertrand P et al (2006) High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of GOELAMS Group. Bone Marrow Transplant 38:417–420. doi: 10.1038/sj.bmt.1705452 PubMedCrossRefGoogle Scholar
  5. 5.
    Montemurro M, Kiefer T, Schuler F et al (2007) Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 18:665–671. doi: 10.1093/annonc/mdl458 PubMedCrossRefGoogle Scholar
  6. 6.
    Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C, Finke J (2008) High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93:147–148. doi: 10.3324/haematol.11771 PubMedCrossRefGoogle Scholar
  7. 7.
    Chamberlain MC, Johnston SK (2010) High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro-Oncology 12:736–744. doi: 10.1093/neuonc/noq011 PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Rubenstein JL, His ED, Johnson JL et al (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31:3061–3068. doi: 10.1200/JCO.2012.46.9957 PubMedCrossRefGoogle Scholar
  9. 9.
    DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group 93-100. J Clin Oncol 20:4643–4648PubMedCrossRefGoogle Scholar
  10. 10.
    Batchelor TT, Carson K, O’Neill A, Grossman SA, Alavi J, New P et al (2003) NABTT CNS Consortium: the treatment of primary central nervous system lymphoma (PCNSL) with methotrexate and deferred radiotherapy—NABTT 96-07. J Clin Oncol 21:1044–1049PubMedCrossRefGoogle Scholar
  11. 11.
    Ferreri AJ, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomized phase 2 trial. Lancet 374:1512–1520. doi: 10.1016/S0140-6736(09)61416-1 PubMedCrossRefGoogle Scholar
  12. 12.
    Doolittle ND, Miner ME, Hall WA et al (2000) Safety and efficacy of a multicenter study using intra-arterial chemotherapy in conjunction with osmotic opening of the blood–brain barrier for the treatment of patients with malignant brain tumors. Cancer 88:637–647. doi: 10.1002/(SICI)1097-0142(20000201 PubMedCrossRefGoogle Scholar
  13. 13.
    Plotkin SR, Betensky RA, Hochberg FH et al (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10:5643–5646. doi: 10.1158/1078-0432.CCR-04-0159 PubMedCrossRefGoogle Scholar
  14. 14.
    Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23:1507–1513. doi: 10.1200/JCO.2005.01.161 PubMedCrossRefGoogle Scholar
  15. 15.
    Hottinger AF, DeAngelis LM, Yahalom J et al (2007) Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69:1178–1182. doi: 10.1212/01.wnl.0000276986.19602.c1 PubMedCrossRefGoogle Scholar
  16. 16.
    Reni M, Zaja F, Mason W et al (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96:864–867. doi: 10.1038/sj.bjc.6603660 PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Fischer L, Thiel E, Klasen HA et al (2006) Prospective trial of topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 17:1141–1145. doi: 10.1093/annonc/mdl070 PubMedCrossRefGoogle Scholar
  18. 18.
    Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T (2008) Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 86:211–215PubMedCrossRefGoogle Scholar
  19. 19.
    Batchelor TT, Grossman SA, Mikkelsen T et al (2011) Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 76:929–930PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Wong ET, Tishler R, Barron L, Wu JK (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101:139–145. doi: 10.1002/cncr.20339 PubMedCrossRefGoogle Scholar
  21. 21.
    Enting RH, Demopoulos A, DeAngelis LM et al (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901–903. doi: 10.1212/01.WNL.0000137050.43114.42 PubMedCrossRefGoogle Scholar
  22. 22.
    Herrlinger U, Brugger W, Bamberg M et al (2000) PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54:1707–1708PubMedCrossRefGoogle Scholar
  23. 23.
    Raizer J, Rademaker A, Evens AM et al (2012) Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer 118:3743–3748. doi: 10.1002/cncr.26709 PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J (2013) Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol 115(1):71–77PubMedCrossRefGoogle Scholar
  25. 25.
    Soussain C, Suzan F, Hoang-Xuan K et al (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742–749PubMedGoogle Scholar
  26. 26.
    Hoy SM (2012) Bendamustine: a review of its use in the management of chronic lymphocytic leukemia, rituximab-refractory indolent non-Hodgkin’s lymphoma and multiple myeloma. Drugs 72:1929–1950. doi: 10.2165/11209510-000000000-00000 PubMedCrossRefGoogle Scholar
  27. 27.
    Moskowitz AJ (2012) Novel agents in Hodgkin lymphoma. Curr Oncol Rep 14:419–423. doi: 10.1007/s11912-012-0251-y PubMedCrossRefGoogle Scholar
  28. 28.
    Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27:1492–1501. doi: 10.1200/JCO.2008.18.7252 PubMedCrossRefGoogle Scholar
  29. 29.
    Chamberlain MC, Johnston SA (2011) Salvage chemotherapy with single agent bendamustine for recurrent glioblastoma. J Neurooncol 105:523–530. doi: 10.1007/s11060-011-0612-7 PubMedCrossRefGoogle Scholar
  30. 30.
    Abrey LE, Batchelor TT, Ferreri AJ et al (2005) Report of an International Workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23(22):5034–5043PubMedCrossRefGoogle Scholar
  31. 31.
    Arellano-Rodrigo E, López-Guillermo A, Bessell EM et al (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70:219–224PubMedCrossRefGoogle Scholar
  32. 32.
    McLaughlin P, Velasquez WS, Redman JR et al (1988) Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst 80:1408–1412PubMedCrossRefGoogle Scholar
  33. 33.
    Omuro A, Tailandier L, Chinot O et al (2011) Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? J Neurooncol 104:323–330. doi: 10.1007/s11060-010-0497-x PubMedCrossRefGoogle Scholar
  34. 34.
    Chamberlain MC (2013) Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin’s lymphoma (NHL): a case series. J Neurooncol 113:27–32. doi: 10.1007/s11060-010-0497-x PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Neuro-Oncology, Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care AllianceUniversity of WashingtonSeattleUSA

Personalised recommendations